Benzbromarone Market Size, Share, Growth, and Industry Analysis, By Type (Tablets and Capsules) By Application (Acute Gout and Chronic Gout), and Regional Forecast to 2032

BENZBROMARONE MARKET OVERVIEW

The global benzbromarone market size expanded rapidly XX in 2023 and is projected to grow substantially XX by 2032, exhibiting a prodigious CAGR XX during the forecast period.

Benzbromarone is a pharmaceutical drug which helps in lowering the uric acid levels in the blood. It is a uricosuric agent. One of its most common uses is to treat gout. Gout is a condition wherein there is an excess of uric acid which leads to formation of urate crystals in the joints. It causes inflammation and pain in the affected regions.

Although benzbromarone is a useful drug, its availability is limited to certain regions due to concerns raised on some of its potential side effects, primarily liver toxicity, which has caused a strict scrutiny of its usage in some countries.

GLOBAL CRISES IMPACTING BENZBROMARONE MARKETCOVID-19 IMPACT

Benzbromarone Industry Had a Negative Effect Due to Disruption in Supply Chain during COVID-19 Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic negatively impacted the healthcare sector as a whole. Due to trade restrictions and low availability of benzbromarone, the manufacture and distribution was halted. To anchor it down further, the pandemic also resulted in huge disruptions in the global supply chain, particularly affecting those nations which primarily relied on the import of the drug and raw materials for their own manufacture and distribution. Amidst all this, the treatment of chronic diseases such as gout was sidelined to treat the COVID patients, thus reducing focus and usage of benzbromarone as a whole.

LATEST TREND

"Increased Focus on Gout Management to Promote Benzbromarone Usage"

Benzbromarone has remained an important cure for gout even today. With patients who do not take well to the use of other therapies like allopurinol, the drug has become their saviour. Globally, researchers have linked the problem of gout to everyday issues faced by many such as obesity, poor dietary habits and especially the aged population. These factors have contributed massively in increasing the demand for efficient uric acid curing and lowering drugs, including benzbromarone. In various regions personalised healthcare is being prioritised and given importance. The focus has shifted to tailoring treatment regimens, which has included the use of benzbromarone, for patients under its treatment, who otherwise require alternative therapies due to potential side effects from intaking other medications to treat uric acid problems.

BENZBROMARONE MARKET SEGMENTATION

BY TYPE

Based on Type, the global market can be categorized intoTablets and Capsules

• Tablets: Tablets are a stabler source of medication which are in the form of solid doses. The benzbromarone capsules are taken with water, similar to how capsules are consumed. They are much more concentrated in nature and deliver the ingredients in the right amount as needed. Tables are cost effective and cheaper to manufacture compared to capsules. They are also easy to store and handle, as patients are much familiar with the dosage form.
• Capsules: Capsules are a very common form in which medications are sold. Capsules provide the patients a convenient way to take their medicine. In benzbromarone capsules, the active ingredient is enclosed in a gelatin encasing, which when consumed, dissolves in the stomach. Patients who have difficulty swallowing usually opt for capsules as an alternative. Capsules tend to release the contents in  a more consistent manner.

BY APPLICATION

Based on application, the global market can be categorized into acute gout and chronic gout

• Acute Gout: Acute gout is commonly identified by sudden and severe pain or swelling and even inflammation in the joints of patients. It occurs due to the excess deposition of uric acid crystals in the joint region. Benzbromarone is primarily used as a long term uric acid lowering drug, but in certain situations, when a patient faces acute attacks, it is used to control and manage the acid levels. It is also used when other medicines and treatments are deemed to be ineffective in cure. Commonly, to treat acute gout, medicines such as colchicine, NSAIDs, and corticosteroid are prescribed.
• Chronic Gout: In case the uric acid levels do not get under control and remain elevated over a period of time, the situation tends for chronic gout occurrence. Common indicators are flare-ups, damage in the affected join, and the formation of uric acid deposits, referred to as tophi. Benzbromarone is used in chronic gout to manage and lower the acid content. It helps in reducing the serum uric acid levels and prevents further future attacks. It is particularly used in cases where patients are unable to tolerate other agents that lower acid levels like allopurinol due to the side effects that come with them such as live toxicity and allergic skin reactions.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.                  

DRIVING FACTORS

"Increased Prevalence of Gout to Prompt Rise in Demand "

Gout has become a prevalent issue worldwide, affecting those in the ageing population and regions with a high rate of metabolic diseases commonly obesity, hypertension and diabetes. These have driven the demand for the drug in the market. As gout is becoming a more common issue faced by patients, there has grown a need for effective uric acid lowering medications. Benzbromarone has found itself in the forefront as it is demanded heavily due to its safer alternative usage and easy to ingest property. This has fuelled the demand for Benzbromarone in the market.

"Preference for Alternative Medications to Increase Benzbromarone Usage"

With several uric acid lowering therapies existing in the market such as allopurinol and febuxostat, benzbromarone has come up as an alternative solution. Patients who suffer from the side effects after ingesting allopurinol or febuxostat have shifted to benzbromarone. Common side effects include skin rashes or gastrointestinal issues or patients with a record of kidney problems. Additionally, it has proved to be a different method as its action increases uric acid excretion through the kidney excretions.

RESTRAINING FACTOR

"Potential Side Effects to Lower Consumption"

Uric acid lowering agents are known for several side effects arising when consuming them to treat gout. Liver Toxicity has become a prominent and well known side effect. In certain regions due to such restraining factors, regulatory restrictions have led to a reduction of the market in certain key areas. Benzbromarone has proved to be an effective treatment to lower uric acid content, still the safety concerning the liver function has been a rising issue. In case of its usage a regular liver monitoring and associated risks will have to be studied in the patient. In order to avoid such hassles, doctors may be hesitant to use the drug.

OPPORTUNITY

"Expanding Use of Drug to Expand into Emerging Markets"

With a rise in metabolic disorders and change in lifestyles, gout has become a recurring problem faced by many patients. Benzbromarone has come up as a cheaper and effective treatment to the problem. Within the emerging markets, it has proved to be cost effective, and is one of the most sought after medicines. Improving healthcare and a rise in the demand for cure to chronic diseases, benzbromarone has the potential to grow and expand in the market.

CHALLENGE

"Alternatives to Benzbromarone to Increase Market Competition"

One of the most significant challenges faced by  benzbromarone market growth is the rise in the number of alternative drugs to it. Febuxostat, lesinurad and pegloticase are emerging as alternatives to benzbromarone. They offer completely different mechanisms of action and are even considered much safer to some extent. The intense competition that has arrived in the market has made it difficult for benzbromarone to have a strong foothold in the market share. And with restrictions and regulatory policies in place, the countries and doctors are looking up to different solutions.

BENZBROMARONE MARKET REGIONAL INSIGHTS

• NORTH AMERICA

North America holds a significant share in the benzbromarone market. It is primarily due to rising gout and related disorders that it has become prevalent in the United States benzbromarone market. The US has become one of the largest markets for uricosuric medications, with the demand driven by the ageing population and a rising awareness on gout treatment. Additionally, advanced technology and medical research has significantly contributed to the region's growth.

• EUROPE

The region is one of the major markets for benzbromarone supported by increasing expenditure in healthcare, an ageing population and increasing uric acid problems. Nations like Germany and the UK have been some key players. Even the European Medicines Agency and national regulatory bodies have given approval to the usage of benzbromarone for treating gout and is well-established in some countries in the region.

• ASIA

Asia is one of the fastest growing regions. In countries such as China and Japan, gout has become a rising concern due to the lifestyle led by the people. Growing infrastructure and increased awareness are facilitating the adoption of benzbromarone as a treatment for gout. As the healthcare improves in countries like India, the rise of benzbromarone market share improvises.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market Through Innovation and Market Expansion"

Key enterprises have shaped the benzbromarone market through innovation, expansion and rapidly growing healthcare. The market has evolved over the years with the key focus being on safety of patients, regulations and providing effective and affordable treatment options. The continued development of drug formulations by companies have resulted in a generic benzbromarone which is easily accessible to the patients. Additionally, the market expansion strategies followed by the companies have resulted in establishing their presence in the emerging market. With improvement in the research and development field, the market for the drug can grow exponentially.

LIST OF TOP GAME PUBLISHER COMPANIES

• Sanofi (France)
• Krka (Slovenia)
• Japan Tobacco Inc (Japan)
• Leadiant Biosciences (US)
• Excella GmbH (Germany)
• Yichang Hec Changjiang Pharmaceutical (China)
• Changzhou Kangpu Pharmaceutical (China)
• Chengdu Taihe Health Technology Group (China)
• KRRP (China)

 KEY INDUSTRY DEVELOPMENTS

January 2023: Despite having huge concerns on liver toxicity in Japan, it continues to be a major user in the medication. The Japanese ministry of health, labour and welfare, approved and reaffirmed the usage of the drug within the nation. This has led to an established market for benzbromarone in the Asia-Pacific regions.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The benzbromarone market is poised for a continued boom pushed by rapid advancement in technology and advanced research and development and  substituting alternatives with emerging markets in the regions with gout problems. Key industry players are advancing via technological upgrades and strategic marketplace growth, enhancing the demand and effectiveness of the medications in the market. It also aims to establish benzbromarone as the leading treatment to gout..